T. Riley

Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2‐agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers

V. Norris, C. Ambery, T. Riley, 2014, Clinical pharmacology in drug development.

Challenges with Developing In Vitro Dissolution Tests for Orally Inhaled Products (OIPs)

Andrew Cooper, D. Christopher, S. Lyapustina, 2012, AAPS PharmSciTech.

Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system.

B. Chowdhry, M. Snowden, M J Snowden, 2001, International journal of pharmaceutics.